Immune‐related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single‐center retrospective study in Japan

Objectives To evaluate the effectiveness and safety of the combination of beraprost sodium (BPS) and aspirin in patients with acute ischemic stroke (AIS). Methods There were 384 patients with AIS enrolled in this single-center, retrospective study. The BPS group comprised patients who received combination therapy with BPS and aspirin, and the control group comprised those who received only aspirin. Primary measurements were glomerular filtration rate (GFR), cystatin-c (Cys-C), National Institute of Health Stroke Scale (NIHSS) score, modified activities of daily living index (MBI), modified Rankin scale (mRS), and blood coagulation indexes. Recurrence and adverse events were recorded. Results There were no significant differences in patient characteristics at baseline between the two groups. GFR and Cys-C levels increased in the BPS group compared with the control group. After treatment, the NIHSS and mRS score were significantly lower in the BPS group compared with the control group, whereas the MBI scores were significantly higher in the BPS group compared with the control group. There was no significant difference in blood coagulation between the two groups. There were no serious adverse events in either group. Conclusions Combination therapy with BPS and aspirin may be a safe and effective treatment for AIS.

Download Full-text

Risk factors for early and late procedure-related adverse events in percutaneous endoscopic gastrostomy: A single center, retrospective study

Journal of Gastroenterology and Hepatology ◽

10.1111/jgh.14407 ◽

2018 ◽

Vol 34 (2) ◽

pp. 404-409 ◽

Cited By ~ 4

Author(s):

Jan Peveling-Oberhag ◽

Imad Osman ◽

Dirk Walter ◽

Natalie Filmann ◽

Katharina Stratmann ◽

...

Keyword(s):

Risk Factors ◽

Retrospective Study ◽

Adverse Events ◽

Percutaneous Endoscopic Gastrostomy ◽

Single Center ◽

Endoscopic Gastrostomy

Download Full-text

Safety of endoscopic sphincterotomy in patients undergoing antithrombotic treatment: a retrospective study

Therapeutic Advances in Gastrointestinal Endoscopy ◽

10.1177/2631774519846327 ◽

2019 ◽

Vol 12 ◽

pp. 263177451984632 ◽

Cited By ~ 1

Author(s):

Akira Yamamiya ◽

Katsuya Kitamura ◽

Yu Ishii ◽

Yuta Mitsui ◽

Hitoshi Yoshida

Keyword(s):

Retrospective Study ◽

Adverse Events ◽

Hospital Stay ◽

Endoscopic Retrograde Cholangiopancreatography ◽

Endoscopic Sphincterotomy ◽

Length Of Hospital Stay ◽

Treatment Discontinuation ◽

Single Center ◽

Antithrombotic Treatment ◽

Endoscopic Retrograde

Background: This study investigated the safety of endoscopic sphincterotomy in patients undergoing antithrombotic treatment. Methods: From January 2014 to December 2016, a single-center retrospective study was conducted. Of the 80 patients with naïve papilla receiving antithrombotic treatment who underwent endoscopic sphincterotomy, 76 patients were retrospectively analyzed. We divided the participants into two groups as follows: 45 patients who discontinued antithrombotic treatment (discontinuation group) and 31 patients who continued antithrombotic treatment (continuation group). We evaluated the safety of endoscopic sphincterotomy in patients with naïve papilla who received antithrombotic treatment. Results: The percentage of patients requiring emergency endoscopic retrograde cholangiopancreatography in the continuation group was significantly higher than that in the discontinuation group (55% vs 11%; p = 0.001). The incidence of adverse events did not differ significantly between the two groups. Neither bleeding nor perforation occurred in either group. The length of hospital stay did not differ significantly between the two groups. Conclusions: Endoscopic sphincterotomy in patients undergoing antithrombotic treatment may be safe if the guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment are followed.

Download Full-text

Reactogenicity of COVID-19 vaccine in hemodialysis patients: a single-center retrospective study

10.1101/2021.11.21.21266561 ◽

2021 ◽

Author(s):

Gaetano Alfano ◽

Niccol&oacute Morisi ◽

Fontana Francesco ◽

Roberta Scarmignan ◽

Laura Tonelli ◽

...

Keyword(s):

Retrospective Study ◽

General Population ◽

Adverse Events ◽

Hemodialysis Patients ◽

Injection Site Pain ◽

Single Center ◽

Observational Period ◽

Age Related ◽

Maintenance Dialysis ◽

Site Pain

Introduction Some hemodialysis patients are reluctant to COVID-19 for the development of adverse events (AEs). The aim of this study was to verify the safety of mRNA-1273 vaccine in hemodialysis patients. Methods We conducted a retrospective analysis of in-center hemodialysis patients who underwent mRNA-1273 vaccine from March 1st to April 30th, 2021. All AEs occurring after the first and the second doses were collected and classified as local or systemic. Results Overall, 126 patients on chronic maintenance dialysis were vaccinated with two doses of mRNA-1273 vaccine. Mean age was 68 (IQR, 54,7-76) years and 53.6% of patients were aged ≥ 65 years. During the observational period of 68 (IQR, 66-70) days, AEs occurred in 57.9% and 61.9% of patients after the first dose and second dose, respectively. The most common AEs were: injection-site pain (61.9%), erythema (4.8%), itching (4.8%), swelling (16.7%), axillary swelling/tenderness (2.4%), fever (17.5%) headache (7.9%), fatigue (23.8%), myalgia (17.5%), arthralgia (12.7%), dyspnoea (2.4%); nausea/ vomiting (7.1%), diarrhoea (5.6%), shivers (4%) and vertigo (1.6%). The rates of local AEs were similar after the first and second doses (P=0.8), whereas systemic AEs occurred more frequently after the second dose (P=0.001). Fever (P=0.03), fatigue (P=0.02) and nausea/vomiting (P=0.03) were significantly more frequent after the second dose of vaccine. There were no age-related differences in the rate of AEs. Overall, vaccine-related AEs in hemodialysis patients seem lower than in the general population. Conclusion RNA-1273 vaccine is associated with the development of transient AEs after the first (57.9%) and second dose (61.9%) in patients on chronic maintenance dialysis. Systemic AEs were more common after the second dose. Overall, all AEs lasted for a few days, without any apparent sequelae.

Download Full-text